Journal of AIDS and HIV Treatment
Volume 3, Issue 2, p21-41
Articles published in this issue are Open Access and licensed under Creative Commons Attribution License (CC BY NC) where the readers can reuse, download, distribute the article in whole or part by mentioning proper credits to the authors.
Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
Among women living with HIV (WLWH), increases in body weight and body mass index (BMI, kg/m2) have been observed after switching to the antiretroviral therapies (ART) - Integrase Inhibitors (INSTI) and/or Tenofovir Alafenamide (TAF).J AIDS HIV Treat, 2021, Volume 3, Issue 2, p21-23 | DOI: 10.33696/AIDS.3.016
Commentary – HIV-Induced Extracranial Carotid Ectasia and Stroke
HIV is a known risk factor for both ischemic and hemorrhagic stroke. Even with the widespread use of antiretroviral therapy, stroke incidence is higher in patients with HIV compared to non-HIV control subjects.J AIDS HIV Treat, 2021, Volume 3, Issue 2, p24-26 | DOI: 10.33696/AIDS.3.017
Pre-Exposure Prophylaxis (PrEP) Safety and Tolerability in Individuals ≥ 45 Years Old
Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral medications, most commonly prescribed as two co-formulated antiretrovirals, taken as a single tablet daily to significantly reduce the risk of human immunodeficiency virus (HIV) infection in individuals at high risk.J AIDS HIV Treat, 2021, Volume 3, Issue 2, p27-30 | DOI: 10.33696/AIDS.3.018
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Fostemsavir (Rukobia™, ViiV Healthcare, Research Triangle Park, NC), a prodrug of the first-in-class attachment inhibitor temsavir, was developed to provide a much-needed new therapeutic option for heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) who are unable to form a suppressive regimen from remaining viable antiretroviral (ARV) agents because of multidrug resistance, contraindications, prior intolerance, or other safety considerations.J AIDS HIV Treat, 2021, Volume 3, Issue 2, p31-36 | DOI: 10.33696/AIDS.3.019
Toward Personalized Medicine for HIV/AIDS
In 2019, approximately 38 million people were infected with HIV worldwide . Although there is still no cure that successfully eradicates the disease, combination antiretroviral therapy (cART) has improved to a point where undetectable viral loads have become achievable and HIV carriers often live almost normal lives with very substantially increased average life expectancies compared to historical data.J AIDS HIV Treat, 2021, Volume 3, Issue 2, p37-41 | DOI: 10.33696/AIDS.3.020
Primary Lymph Node Kaposi's Sarcoma in Two HIV Positive Patients Presenting with Generalized Lymphadenopathy and Pancytopenia in a Third Level Hospital in Guatemala
We present two unique cases in which two HIV positive patients with generalized lymphadenopathy and pancytopenia without any skin lesions were diagnosed with primary lymph node Kaposi´s Sarcoma after excisional biopsy of an inguinal lymph node.
CCR5 Inhibitors and HIV-1 Infection
Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR5 as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR5 ligand ?-chemokines , resulted in the development of new viral entry inhibitors to block CCR5 binding, including both- small molecules and CCR5 antibodies
The Impact of Marginalization on the Continuum of Care Treatment Model on African American Communities in the Southern United States
Recently, I was asked to speak at the National Academy of Public Administration (NAPA) Conference about my experiences serving as an ethnographic consultant on the National HIV Behavioral Surveillance System (NHBS1 ) Study.
Recent Progress in Preclinical HIV-1 Vaccine Research
Since isolation in humans in 1983 [1,2], HIV-1 has developed into a global pandemic. But an effective HIV-1 vaccine has not been succeeded despite multiple human vaccine trials performed [3,4]. Challenges to an effective vaccine arise from intrinsic virological and immunological features of HIV-1 [3-8].
Anti-HIV-1 Activity of Crocodylus mindorensis (Philippine Crocodile) Serum in Cell-free and Cell-associated Virus Interactions to Human Peripheral Blood Mononuclear Cells
Highly-Active Antiretroviral Therapy (HAART) is the recommended treatment and management strategy for HIV infection. Although the existing antiretroviral drugs are indispensably significant in improving the quality and extending the lives of HIV/ AIDS individuals, the drugs still have many limitations including development of resistance, production of toxicity, and their limited availability.
Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally .
Health Workers’ Perspectives on the Outcomes, Enablers, and Barriers to the Implementation of HIV “Test and Treat” Guidelines in Abuja, Nigeria
HIV/AIDS continues to be a major public health disease accounting for 35 million deaths across the world. In 2016 alone, there were 1.8 million new HIV infections and 1 million deaths worldwide.
HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia
For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35.0 million [28.9 million-41.5 million] lives and at its peak threatened global stability and security.
Rate and Predictors of Treatment Failure among Pediatric Population Taking Highly Active Antiretroviral Therapy in Ethiopia
The global scaling up of treatment and care for people living with Human Immunodeficiency Virus (PLHIV) has led to a 43% decline in new HIV pediatric infections since 2003, with 330,000 newly infected children in 2011.
Development of an Ultrasensitive HIV-1 DNA Detection Assay Based on an Automated πCode End-Point PCR System
Currently, around 60-75% of the HIV positive patients in developed countries on anti-retroviral therapy (ART) have undetectable plasma viral load using current diagnostic PCR assays.
Patient-Reported Health Outcomes among HIV-Infected Patients on Antiretroviral Therapy in a Tertiary Hospital in Dar Es Salaam, Tanzania: A Cross Sectional Study
The use of antiretroviral therapy (ART) has resulted into HIV-infected patients living longer than it was the case in the pre-ART era . Surviving patients are concerned not only with the treatment ability to extend their lives but also that their quality of life is improved on the course.
Black Women's Contribution to the HIV/AIDS Fight
After thousands of years of gender conflicts, the world now stands at the beginning of the feminine era, when women will rise to their proper standing, and the entire world will experience the harmony between men and women.
Use of Humanized Mouse Models for Studying HIV-1 Infection, Pathogenesis and Persistence
Different humanized mouse models have been introduced to enable HIV-1 research in vivo, which has been made possible by the development of immunodeficient mouse strains.
Metabolic Syndrome in HIV Infected Children Receiving Free HAART at a Centre of Excellence in HIV Care in Northern India
Implementation of Highly Active Antiretroviral Therapy (HAART) for patients with HIV has led to the dramatic reduction in AIDS related mortality in both children and adults . With their longer life expectancy and improved quality of life, effects of ageing and other environmental factors are predisposing them to non-AIDS related morbidities, with cardiovascular diseases emerging as an important threat.
Unveiling an Atypical Response to HIV-1 Infection by the Patient Carrier of the Beta-S Globin Gene and Duffy Antigen Gene Double Mutation
It is known and well documented that genetic selective pressures occur from Plasmodium falciparum, P. vivax or P. knowlesi infection of red blood cells, such led to the selection of their cell membrane antigens, hemoglobin and enzymes thus associated to several mutation including, among others.
Older Versus Younger Men Who Have Sex with Men: Awareness of and Potential Barriers to the Use of Pre-Exposure Prophylaxis (PrEP) Medication to Prevent the Transmission of HIV
Men who have sex with other men (MSM) comprise the single largest group of individuals contracting HIV in the United States, accounting for more than one-half of all new HIV diagnoses.
Trend of HIV Infection in a Specialized Medical Unit, 2007- 2016
The human immunodeficiency virus (HIV) has caused one of the pandemics that has most affected the world population , and continues to be a serious problem, since to date it has not been possible to eradicate or prevent totally new cases.
AIDS Related Histoplasmosis, Treatment and Prophylaxis: the Mycology Unit of FJ Muniz Hospital Experience
Classic histoplasmosis is a systemic endemic mycosis due to the dimorphic fungus Histoplasma capsulatum var. capsulatum. This microorganism lives as mold in rich nitrogen soil in temperate and humid regions.
Anaphylaxis Drug Reaction after Initiation of Bictegravir
A 44-year old Ethiopian female with a history of HIV and latent tuberculosis treated with three months of rifampin presented to the Ruth M Rothstein CORE Center complaining of pruritic rash that started the previous night.
Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations
At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.